Price (90d)
$176.86Signal Score (90d)
160Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $21.84B | $1.68B | $5.84 |
| 2024 | $20.18B | $1.71B | $5.88 |
| 2023 | $19.37B | $1.48B | $4.97 |
| 2022 | $18.87B | $1.78B | $5.93 |
| 2021 | $19.13B | $2.09B | $6.92 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $4.06 per share
Typical surprise +4.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$3.23 vs $3.14beat
- Thu, May 7$2.90 vs $2.78beat
- Mon, Feb 9$2.91 vs $2.21beat
- Thu, Nov 6$3.96 vs $3.92beat
- Thu, Aug 7$3.68 vs $3.40beat
- Thu, May 1$3.35 vs $3.28beat
Estimates and results for BDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from BDX's reported EPS growth of -4.2% a year over 4 years.
- EPS in 5 years
- $4.72
- Implied price
- $118.10
- Return from $183.40
- -8.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $58.72 — -68.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 17 | 21 | 25 | 29 | 33 |
|---|---|---|---|---|---|
| -14.2% | -24.1% | -20.8% | -18.0% | -15.5% | -13.3% |
| -9.2% | -19.6% | -16.2% | -13.2% | -10.6% | -8.2% |
| -4.2% | -15.2% | -11.6% | -8.4% | -5.7% | -3.2% |
| 0.8% | -10.8% | -6.9% | -3.6% | -0.7% | 1.9% |
| 5.8% | -6.4% | -2.3% | 1.1% | 4.2% | 6.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (4)
- Newszacks.com·2d ago·Neutral
Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.
View source ↗ - Newsseekingalpha.com·2d ago·Positive
Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.
View source ↗ - Newsprnewswire.com·3d ago·Neutral
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion e
View source ↗ - Newsmarketbeat.com·7d ago·Neutral
Becton, Dickinson and Company Q3 Earnings Call Highlights Becton, Dickinson and Company NYSE: BDX reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company's expectations.
View source ↗